GoBroad Healthcare Group
Shanghai
, China
10
reviews
Price level Medium
7
GoBroad hospitals in Beijing, Shanghai, and Guangzhou
2017
year of establishment of the medical group
1500
beds in the GoBroad network
5000
patients who underwent CAR-T therapy at GoBroad clinics
80+
countries from which patients come for treatment
About clinic
GoBroad Healthcare Group is a modern medical network in China specializing in the treatment of lung, breast, stomach, and intestinal cancers, as well as hematologic malignancies, using advanced biotechnologies. The group also successfully treats autoimmune and neurological disorders. Founded in 2017, GoBroad operates seven clinics in Beijing, Shanghai, and Guangzhou and participates in over 650 clinical trials. Physicians employ innovative therapeutic methods that are not yet widely available in standard practice.
GoBroad doctors adhere to the principles of personalized medicine. They utilize expanded genetic panels, NGS sequencing, and immunophenotyping to precisely select therapies. The medical group has extensive experience in CAR-T immunotherapy and hematopoietic stem cell transplantation for resistant forms of leukemia, lymphoma, and myeloma.
Advantages of GoBroad Healthcare Group
GHG combines modern infrastructure with a research-driven approach. Key benefits of the network include:
- Availability of innovative equipment and advanced diagnostic platforms that allow testing for nearly 30 tumor targets across various cancer types.
- Personalized and highly precise treatment programs tailored to the clinical condition and individual needs of each patient.
- One of the world's most experienced CAR-T therapy centers, with over 5,000 successfully treated patients.
- More affordable CAR-T treatment compared to other countries—on average around $60,000.
- Over 50 published scientific papers whose results are recognized by the international medical community.
Treatment of Solid Tumors at GoBroad Healthcare Group
GoBroad Healthcare Group treats a wide range of solid tumors, including stomach and intestinal cancers, gastrointestinal tumors, lung, liver, pancreatic, biliary tract, and breast cancers.
Diagnostics include early screening, high-precision tumor detection, and comprehensive molecular analysis (NGS, immunohistochemistry, liquid biopsy) to identify key mutations (EGFR, ALK, KRAS G12C, HER2, KIT/PDGFRA, PD-L1, MSI-H) and select the most effective therapy.
Depending on tumor type and stage, modern treatment methods are applied:
- Surgery, chemotherapy, and radiotherapy;
- Targeted therapies;
- Immunotherapy with checkpoint inhibitors;
- Interventional procedures (chemoembolization, radiofrequency ablation);
- Cell therapy for resistant cancer forms.
For complex, recurrent, and advanced tumors, clinical trials of new drugs and combined therapeutic regimens are available.
Hematologic Malignancy Treatment at GoBroad Healthcare Group
GHG specializes in the diagnosis and treatment of severe blood disorders, including various forms of leukemia, lymphoma, multiple myeloma, and thalassemia.
Treatment is based on high-precision molecular diagnostics:
- NGS sequencing;
- Cytogenetic analyses;
- Flow cytometry and liquid biopsy to determine cancer subtypes;
- Mutation identification and minimal residual disease assessment.
Therapies are individually tailored and include modern combinations of chemo- and radiotherapy, targeted and immunotherapy, as well as stem cell transplantation.
Cellular therapy is a key focus: GoBroad performs single- and dual-target CAR-T protocols, as well as sequential CAR-T regimens for relapsed and resistant diseases.
- Acute leukemias – CAR-T therapy, chemotherapy, and subsequent transplants, including allogeneic.
- Lymphomas – risk stratification using NGS data, targeted therapy, and various CAR-T options, including donor-derived CAR-T with subsequent transplantation.
- Multiple myeloma – innovative drugs, CAR-T therapy, and stem cell transplantation, including consolidation regimens.
Pediatric Hematologic Oncology Treatment
GoBroad Healthcare Group treats severe pediatric leukemias and lymphomas using modern cellular therapy, targeted treatment, and stem cell transplantation. Their approach is based on stratified therapy: each child receives a personalized plan considering the tumor's genetic profile, relapse risk, and response to previous treatments.
GoBroad centers have achieved high outcomes: 5-year relapse-free survival for pediatric lymphomas reaches 80%, exceeding international averages (60–70%), and cure rates for certain aggressive forms, including T-cell lymphoblastic lymphoma, exceed 90%.
If you wish to receive treatment at GoBroad Healthcare Group, you can contact us using the method most convenient for you. Experts Medical coordinators will arrange consultations with clinic specialists and provide full medical support. Our services are completely free for patients.
The best specialties of the hospital
Neurology
Oncology
Urology, nephrology
Luo Zixiong
5/5
Clinic: GoBroad Healthcare Group
Diagnosis: myelodysplastic syndrome
A 22-year-old guitarist was admitted to the GHG Medical Center in April 2021 with recurrent epistaxis. After undergoing the necessary examinations, he was diagnosed with myelodysplastic syndrome (MDS). In June 2021, the patient successfully underwent an allogeneic hematopoietic stem cell transplantation. One month and six months after the transplant, however, he developed grade IV intestinal graft rejection. Unable to take in nutrition through the gastrointestinal tract, he was dependent solely on parenteral nutrition, which posed a major challenge for maintaining adequate energy intake, protecting vital organs, and managing multiple complications. After active and comprehensive treatment provided by the GHG medical team, the patient finally overcame the disease. More than two years after the allogeneic transplantation, he completed follow-up care and achieved complete remission of the underlying condition with a good overall recovery. He has now returned to normal work and daily life.
“I was discharged from the transplant unit after 20 days. At that time, I felt very optimistic, but I was also deeply afraid that I would develop severe intestinal rejection after leaving the hospital. My attending physician is the best doctor I have ever met in any hospital. While I was hospitalized, whenever I felt unwell, I called her, and she would come and gently ask, ‘Baby, what’s wrong?’ I stayed in the hospital for such a long time, yet remained in good spirits thanks to her care. She continued answering my questions even after I returned home and wasn’t feeling well. I am grateful to the GHG medical team for saving my life and healing both my physical and emotional wounds.”
20/01/2025
Mr.W
5/5
Clinic: GoBroad Healthcare Group
Diagnosis: Paroxysmal Hemoglobinuria
Mr. W’s story and his struggle with paroxysmal nocturnal hemoglobinuria (PNH) began nine years ago. For a long time, he experienced persistent fatigue and shortness of breath, initially attributing these symptoms to his workload. However, the symptoms gradually worsened, until one day his urine turned a dark, “soy sauce–like” color—an alarming sign that could not be ignored. Examination at a local hospital confirmed the diagnosis: PNH combined with aplastic anemia (AA), a rare acquired clonal disorder of hematopoietic stem cells characterized by intravascular hemolysis, bone marrow suppression, and a high risk of thrombosis. For many years, he required hormone therapy and periodic blood transfusions, yet his hemoglobin level remained at 50–60 g/L, causing severe weakness and greatly reducing his quality of life.
At the beginning of 2024, his condition deteriorated sharply: hemolytic episodes became more frequent, hemoglobin dropped below 40 g/L, and he experienced increasing abdominal pain and a greater need for transfusions. As a teacher, Mr. W thoroughly researched information about the disease and learned that PNH combined with AA can be cured through allogeneic hematopoietic stem cell transplantation (allo-HSCT). HLA typing revealed that his brother was a fully matched donor. On the recommendation of other patients, he sought treatment at the GoBroad Chunfu Institute.
After a comprehensive evaluation, Director Zeng presented two treatment options: lifelong complement inhibitor therapy to control symptoms, or stem cell transplantation from a fully matched donor to achieve complete cure. After discussing the options with his family, Mr. W chose transplantation. Prior to the procedure, he received eculizumab, which effectively reduced hemolysis and increased his hemoglobin level to 94 g/L, improving his overall condition.
On October 15, 2024, he was admitted to the transplant unit for pre-transplant conditioning, and on October 24 he received peripheral blood stem cells donated by his brother. During the post-transplant period, he developed several complications, including pneumonia, mucosal ulcers, abdominal pain, headaches, and fever—typical issues for immunocompromised patients. Under the close supervision of Zeng Yuanying and her team, his treatment was adjusted promptly, helping him navigate the most critical stages of recovery. Thanks to professional care and strong family support, his blood counts gradually improved, and by November 15 he successfully met the discharge criteria for leaving the transplant unit.
Commenting on the case, Zeng Yuanying noted that despite advances in complement inhibitor therapy, its effectiveness is limited in patients with combined PNH and AA. Even in the era of targeted therapies, allogeneic stem cell transplantation remains the only curative treatment for PNH. She emphasized that persistent anemia accompanied by signs of hemolysis requires mandatory evaluation for PNH, and timely diagnosis and treatment significantly improve outcomes.
Today, Mr. W continues his recovery, with his condition steadily improving as he gradually returns to a full and active life. The banner he presented stands not only as a token of gratitude but also as a testament to the professionalism, dedication, and high standard of medical care at the GoBroad Chunfu Institute of Hematology and Oncology.
26/12/2024
Yiyi
5/5
Clinic: GoBroad Healthcare Group
Diagnosis: T-cell lymphoblastic lymphoma
After being diagnosed with T-cell lymphoblastic lymphoma at another hospital, Yiyi experienced several central relapses. She received multiple rounds of high-dose methotrexate and repeated intrathecal injections but did not achieve remission. When she was admitted to GHG Medical Centers, Professor Yonghong ZHANG’s team thoroughly reviewed her previous treatments and determined that her symptoms did not align with a central relapse. Further tests revealed that Yiyi had a concurrent cytomegalovirus infection, leading to a diagnosis of cytomegalovirus encephalitis.
Following antiviral treatment, the abnormal cells in her central nervous system disappeared, and Yiyi’s condition improved quickly. Her subsequent treatments went well, and she achieved complete remission, which has persisted. Yiyi, who enjoys singing and dancing, is now able to perform on stage again.
03/10/2024
Lele
5/5
Clinic: GoBroad Healthcare Group
Diagnosis: Hodgkin lymphoma
Lele, a boy, was diagnosed with classical Hodgkin lymphoma in October 2022. At the recommendation of the wardmates, his parents took him to GHG medical center. After a comprehensive examination and evaluation of Lele, the GHG medial team considered not only the current response and cure but also the long-term non-serious toxic and side effects for the therapeutic regimen and finally developed a standardized treatment regimen with precise stratification.
After 6 courses of chemotherapy, Lele has achieved a complete remission. At the time of discharge, he said happily, “I can finally say goodbye to the hospital! I’m sure I’ll have handsome hair! I will run on the playground on sunny days like my classmates!”
12/06/2023
Tiantian
5/5
Clinic: GoBroad Healthcare Group
Diagnosis: Anemia
Seven-year-old Tiantian, who was only one year old in 2017, underwent a hematology test at the local children’s hospital due to persistent fever. The results showed hemoglobin at 50 g/L, and he was diagnosed with major β-thalassemia with a double HBB mutation. When Tiantian was diagnosed, he already showed very obvious symptoms of anemia and required a red blood cell transfusion. As Tiantian grew older, the strain on his circulatory system increased as well. The number of blood transfusions rose from 2 to 3 units each time, almost every other month, to keep his hemoglobin level around 90 g/L.
In 2022, Tiantian and his parents came to the GHG Medical Center. Thanks to the efforts of the medical team, Tiantian underwent a TDH transplant. Today, Tiantian no longer needs medication and has returned to a happy childhood.
“We knew that the success rate of thalassemia transplantation performed by the GHG medical team is 97%, and compared with the possible risks, we chose to trust the team’s many years of experience in thalassemia transplantation. Every month he had to be admitted to the hospital for blood transfusions and iron chelation, and he stayed at least two days each time. Because the injections were so frequent and his blood vessels were narrowing, it often took 2–3 attempts before an injection succeeded. As his parents, it was heartbreaking. We are grateful to the doctors and nurses. It is thanks to them that Tiantian can now have a normal and happy childhood like other children.”
18/12/2022
Linlin
5/5
Clinic: GoBroad Healthcare Group
Diagnosis: lymphoblastic leukemia
Linlin, a 13-year-old girl, was diagnosed with acute B-lymphoblastic leukemia in 2018. However, she had no response to multiple courses of chemotherapy. She received the first hematopoietic stem cell transplant in her hometown in October 2019. Unfortunately, her leukemia relapsed in October 2020.
Linlin came to GHG medical center with her parents for further treatment in 2021. She was recommended to first receive CAR-T treatment, followed by hematopoietic stem cell transplant after careful evaluation by GHG medical team. Accompanied by the GHG team, she successfully received CAR-T therapy and the second hematopoietic stem cell transplant. She went through difficulties including nausea, vomiting, fever, and rejection and was discharged from the hospital. More than two years have passed
since the second transplant, and there have been no other serious post-transplant complications. Linlin said happily, “The sky in Beijing is so blue.” when she walked out from GHG medical center because she had a good re-examination recently.
17/04/2022
Anan
5/5
Clinic: GoBroad Healthcare Group
Diagnosis: acute lymphocytic leukemia
Anan, a girl, was diagnosed with acute lymphoblastic leukemia in 2014 when she was 4 years old, and her condition was stable after multiple courses of chemotherapy for more than 3 years. The patient achieved a response after CAR-T therapy in 2020. She came to GHG medical center for further diagnosis and treatment due to a second relapse of leukemia in 2021.
After reviewing Anan’s past medical history and various examination reports, the team proposed chemotherapy first and completed lumbar puncture intrathecal injection targeting a stable condition. After her condition was initially stable, the team proposed a sequential CAR-T therapy program. The doctor’s rich treatment experience and logically clear treatment thoughts gave Anan’s family confidence.
She achieved a very good response after CAR-T therapy. Although the effect of CART therapy was currently very good, the team recommended seizing the opportunity to bridge allogeneic hematopoietic stem cell transplant after CAR-T therapy according to the latest clinical research and comprehensive judgment of her condition and explained the new program of TDH in detail. Compared with other transplant programs, TDH had lower requirements for donor matching, faster recovery and fewer complications, especially the success rate of transplant, which gave her family great confidence. After the transplant, both Anan’s indicators and mental status were very good. After more than 9 years of fighting with leukemia by chemotherapy, CAR-T, and bridging to allogeneic hematopoietic stem cell transplant after CAR-T therapy, Anan also began to look forward to returning to school after recovery.
24/01/2022
Tian Tian
5/5
Clinic: GoBroad Healthcare Group
Diagnosis: Burkitt lymphoma
In 2017, six-year-old Tian Tian was diagnosed with Burkitt lymphoma. Despite undergoing several rounds of high-dose chemotherapy as the first line of treatment, he did not reach complete remission. He then received second-line chemotherapy, but the tumor continued to grow.
To further address his condition, Tian Tian was treated at GHG Medical Centers. After a thorough evaluation, Professor Yonghong ZHANG created a personalized treatment plan for him. Due to the tumor’s persistent progression, Tian Tian had three biopsies and underwent sequential CAR-T cell therapy targeting CD19, CD22, and CD20. Ultimately, he achieved complete remission, which he has maintained to this day. Now as middle school student, he leads a normal life, studying and enjoying time with friends.
Tian Tian is recognized as the first patient i with refractory/relapsed Burkitt lymphoma (R/R BL) to attain complete remission through the sequential infusion of CD19/CD20/CD22 CAR-T cells. This groundbreaking therapy offers a new treatment option for refractory relapsed Burkitt lymphoma.
24/03/2020
Cost of diagnostics and operations
Hematology / Oncohematology
| Adult leukemia | $30,000–$60,000 | Enquire price |
| Adult lymphoma | $50,000–$80,000 | Enquire price |
| Multiple myeloma | $60,000–$80,000 | Enquire price |
| Pediatric lymphoma | $50,000–$100,000 | Enquire price |
| Oncohematological diseases and autoimmune diseases | $30,000–$150,000 | Enquire price |
| Oncohematological diseases and genetic defects | $100,000–$150,000 | Enquire price |
| Thalassemia (TDT) / Sickle cell disease (SCD) | $150,000–$180,000 | Enquire price |
Oncology / Solid tumors
| Gastrointestinal tumors | $30,000–$120,000 | Enquire price |
| Melanoma | $100,000–$120,000 | Enquire price |
| Sarcoma | $100,000–$120,000 | Enquire price |
| Chest tumors | $100,000–$120,000 | Enquire price |
| Thyroid gland | $100,000–$120,000 | Enquire price |
| Liver cancer | $100,000–$120,000 | Enquire price |
| Gastrointestinal tumors | $100,000–$120,000 | Enquire price |
| Urinary tract tumors | $100,000–$120,000 | Enquire price |
| Gynecological tumors | $100,000–$120,000 | Enquire price |
Autoimmune diseases
| Sjögren's syndrome | $100,000–$150,000 | Enquire price |
| Systemic lupus erythematosus (SLE) | $100,000–$150,000 | Enquire price |
| Rheumatoid arthritis (RA) | $100,000–$150,000 | Enquire price |
| Multiple sclerosis (MS) | $100,000–$150,000 | Enquire price |
| Type 1 diabetes mellitus | $100,000–$150,000 | Enquire price |
| Myasthenia gravis | $100,000–$150,000 | Enquire price |
| Crohn's disease | $100,000–$150,000 | Enquire price |
| Pemphigus vulgaris | $100,000–$150,000 | Enquire price |
| Mixed connective tissue disease (MCTD) | $100,000–$150,000 | Enquire price |
Neurology
| Parkinson's disease (PD) | $60,000–$70,000 | Enquire price |
| Essential tremor (ET) | $30,000 | Enquire price |
Best clinic's doctors
Professor Jin Li
Clinical Oncologist
Work experience:
over 35 years
Achievements:
Specialization:
- Treatment of gastrointestinal malignancies
- Molecular targeted therapy
- Immunotherapy
- Early-phase and multicenter clinical trials of anticancer drugs
- Multidisciplinary management of complex solid tumors
Education:
- Postdoctoral training in tumor genetics and biotherapy at Yale University under the supervision of Professor Alan Garen, a member of the U.S. National Academy of Sciences
Clinical Experience and Scientific Activities:
- President and Chief Scientist of Shanghai GoBroad Cancer Hospital, affiliated with China Pharmaceutical University
- Nationally and internationally recognized expert in gastrointestinal cancers
- Leading specialist in clinical research of innovative anticancer therapies in China
- Author of over 100 publications in top international journals (JAMA, Journal of Clinical Oncology, Lancet Oncology, PNAS, Clinical Cancer Research)
- Actively engaged in translating scientific innovation into clinical practice and promoting China’s anticancer developments globally
Professor Baohui Han
oncologist, pulmonary disease specialist
Work experience:
over 40 years
Achievements:
- Special Allowance of the State Council of China
- Chinese Medical Science and Technology Award
- Chinese Respiratory Physician Award
- Chinese Pharmaceutical Association Science and Technology Innovation Award
Specialization:
- Diagnosis and treatment of pulmonary diseases
- Diagnosis and treatment of lung cancer
- Targeted therapy for lung cancer
- Molecular epidemiology of lung cancer
- Immunotherapy-based combination strategies
- Precision and differential diagnosis
- Multidisciplinary treatment
- Biological immunotherapy and targeted therapy
Education:
- Postdoctoral research in tumor immunotherapy at the Cancer Institute, University of Pittsburgh Medical Center
Clinical Experience:
- Chief Physician, Professor, PhD Supervisor
- Honorary Vice President of Shanghai GoBroad Cancer Hospital, affiliated with China Pharmaceutical University
Scientific Activities:
- Leadership of more than one hundred clinical studies on novel lung cancer therapies
- Leadership of national scientific research projects
Key Studies:
- Third-line therapy clinical trial of the multi-target tyrosine kinase inhibitor anlotinib
- Clinical research of a bevacizumab biosimilar
- More than 100 publications in leading international journals (NEJM, JAMA Oncology, Lancet Oncology)
- Editor-in-chief of major professional books, including the “Guidelines for the Diagnosis and Treatment of Lung Cancer”
Professor Yang Yao
Oncologist
Work experience:
over 30 years
Achievements:
Specialization:
- Bone and soft tissue sarcomas
- Malignant bone metastases
Education:
- Postdoctoral training at Harbor-UCLA Medical Center, USA
Clinical Experience:
- Chief Physician, Professor, Shanghai GoBroad Cancer Hospital, affiliated with China Pharmaceutical University
- Founder and first Executive Director of the Shanghai Sarcoma Clinical Center (SSCC)
- Founder of the Department of Medical Oncology at Shanghai Sixth People’s Hospital
Scientific Activity:
- Over 130 publications in national and international journals, including more than 50 SCI-indexed articles
- Chief editor of the monographs Illustrated Oncology Therapeutics and Diagnosis and Comprehensive Treatment of Malignant Tumors
- Leadership of projects funded by the National Natural Science Foundation of China and major Shanghai scientific programs
- Conducts research and clinical trials in the field of sarcoma therapeutics
Dr. Jun Zhou
oncologist
Work experience:
over 30 years
Achievements:
- Included in the “Top People’s Doctors of China” ranking (Fifth Edition)
Specialization:
- Gastric cancer
- Colorectal cancer
- Malignancies of the liver and pancreas
- Comprehensive treatment of complex and non-standard cases using cellular therapy, molecular targeted therapy, immunotherapy, interventional therapy, and traditional Chinese medicine
Clinical Experience:
- Chief Physician, Master’s Supervisor
- Deputy Medical Director and Director of Gastrointestinal Oncology, Shanghai GoBroad Cancer Hospital, affiliated with China Pharmaceutical University
Research Activities:
- Leadership and participation in over 60 phase I–III clinical trials of novel anticancer drugs
- Leadership and participation in projects funded by the National Natural Science Foundation of China and the Shanghai Science and Technology Commission
- Over 20 publications in journals such as Nature Medicine, GUT, Journal of Cellular Physiology, Journal of Cellular Biochemistry, and Oncotarget
- Contributions to several oncology monographs
- Holds one invention patent
- One of the earliest researchers in China conducting clinical studies of CAR-T, CAR-NK, and TIL therapies for gastrointestinal cancers
- Владение одним патентом на изобретение
- Один из первых исследователей в Китае по клиническим исследованиям CAR-T, CAR-NK и TIL терапии для гастроинтестинальных опухолей
Professor Changxing Lyu
oncologist (radiation therapist)
Work experience:
over 30 years
Achievements:
Specialization:
- Radiation therapy for malignant tumors
- Precision radiotherapy
- Comprehensive management of thoracic malignancies
Education:
- Advanced training at the U.S. National Institutes of Health (NIH)
- MD Anderson Cancer Center
Clinical Experience:
- Chief Physician, Professor, Discipline Leader, Shanghai GoBroad Cancer Hospital, affiliated with China Pharmaceutical University
Research Activities:
- Over 30 publications in leading national and international journals, including International Journal of Cancer, Journal of Thoracic Oncology, Chinese Journal of Radiation Oncology; more than 10 SCI-indexed articles
- Chief editor or co-editor of more than ten professional monographs, including New Radiotherapy and Radiation Oncology
- Principal investigator of research projects funded by the Shanghai Municipal Health Bureau and the National “11th Five-Year” Support Program
Dr. Shuang Li
oncologist
Work experience:
over 20 years
Achievements:
Specialization:
- Comprehensive treatment of malignant tumors
- Management of patients at all stages of therapy
- Application of chemotherapy, targeted therapy, immunotherapy, and radiotherapy
- Particular expertise in applying these methods during neoadjuvant and adjuvant therapy
Education:
- Advanced training at the Oncology Teaching Hospital of Ulm University, Germany
Clinical Experience:
- Chief Physician, Master’s Supervisor
- Director, Department of Oncology II, Shanghai GoBroad Cancer Hospital, affiliated with China Pharmaceutical University
Research Activities:
- Principal Investigator (PI) of several clinical studies
Additional services
Transfer from / to the airport
Visa assistance
Personal assistant
Wi-Fi Internet
Reservation of accommodation and airline tickets
Translator
Accommodation for accompanying person
Single room
Video about clinic
Send request to clinic
we will contact you within 15 minutes
Clinic on the map
Published 30.11.2025, Updated 16.12.2025